Structure Therapeutics (NASDAQ:GPCR) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $65.00 price objective on the stock.

Several other brokerages have also commented on GPCR. JMP Securities cut their price objective on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a report on Friday, August 9th. BMO Capital Markets increased their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a report on Friday, June 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Structure Therapeutics in a research report on Tuesday, May 21st. They set an overweight rating and a $65.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of Buy and an average price target of $84.63.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $38.26 on Monday. The firm has a fifty day moving average price of $38.09 and a two-hundred day moving average price of $39.64. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -49.69 and a beta of -3.52. Structure Therapeutics has a one year low of $26.61 and a one year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Equities research analysts expect that Structure Therapeutics will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky lifted its stake in Structure Therapeutics by 28.5% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock worth $693,000 after purchasing an additional 3,918 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $1,369,000. Quarry LP purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $79,000. Driehaus Capital Management LLC grew its position in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new position in Structure Therapeutics in the 2nd quarter worth approximately $2,160,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.